STOCKHOLM, Oct. 24, 2024 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research at the Clinical Trials for Alzheimer’s […]
Tag: BioArctic
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM, Oct. 16, 2024 /PRNewswire/ — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to […]
Eisai will request reconsideration of initial decision for lecanemab in Australia
STOCKHOLM, Oct. 17, 2024 /PRNewswire/ — BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia issued a public statement about the initial decision not to […]
Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (brand name, generic name: lecanemab) has been granted Marketing Authorization by the Medicines and Healthcare products Regulatory […]
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
STOCKHOLM, Aug. 22, 2024 /PRNewswire/ — British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) has currently not been informed that the relevant authorities have […]
